Qualigen to participate in next funding round for NanoSynex

Company Overview - Qualigen Therapeutics, Inc. is participating as the first investor in the 2025 bridge funding round for NanoSynex, which aims to raise up to $500,000 [1][2] - NanoSynex is a MedTech company based in Israel focused on developing a rapid Antimicrobial Susceptibility Test (AST) to improve testing quality and reduce healthcare costs [3][4] Technology and Market Potential - The technology being developed by NanoSynex will halve the time required for antimicrobial susceptibility testing, providing more robust diagnostics and better antibiotic usage globally [2] - The global market for AST is expected to reach $4.7 billion by 2027, with the US market projected to reach $1.6 billion [2] - NanoSynex holds four patents protecting its technology, indicating a strong competitive position in the market [2] Product Development and Future Plans - The funding from Qualigen will accelerate the development of NanoSynex's Minimum Viable Product (MVP) system for AST, referred to as generation 2.0 [3] - NanoSynex plans to seek approval for its technology in the EU market by 2027 and in the US by 2028 [2]